The effects of corticotropin-releasing factor (CRF) and urocortins on the noradrenaline (NA) released from the locus coeruleus (LC)

Corticotropin-releasing factor (CRF) activates the hypothalamic-pituitary-adrenal (HPA) axis and stimulates the noradrenergic neurotransmission, both processes being implicated in the pathogenesis of anxiety and depression, but the intimate site and mechanism of interaction of CRF and CRF-related pe...

Teljes leírás

Elmentve itt :
Bibliográfiai részletek
Szerzők: Táncsics Patrícia
Kovács Alíz
Palotai Miklós
Bagosi Zsolt
Dokumentumtípus: Cikk
Megjelent: 2024
Sorozat:PEPTIDES 182
Tárgyszavak:
doi:10.1016/j.peptides.2024.171322

mtmt:35672861
Online Access:http://publicatio.bibl.u-szeged.hu/37900
LEADER 02669nab a2200253 i 4500
001 publ37900
005 20251008112218.0
008 251008s2024 hu o 000 eng d
022 |a 0196-9781 
024 7 |a 10.1016/j.peptides.2024.171322  |2 doi 
024 7 |a 35672861  |2 mtmt 
040 |a SZTE Publicatio Repozitórium  |b hun 
041 |a eng 
100 1 |a Táncsics Patrícia 
245 1 4 |a The effects of corticotropin-releasing factor (CRF) and urocortins on the noradrenaline (NA) released from the locus coeruleus (LC)  |h [elektronikus dokumentum] /  |c  Táncsics Patrícia 
260 |c 2024 
300 |a 6 
490 0 |a PEPTIDES  |v 182 
520 3 |a Corticotropin-releasing factor (CRF) activates the hypothalamic-pituitary-adrenal (HPA) axis and stimulates the noradrenergic neurotransmission, both processes being implicated in the pathogenesis of anxiety and depression, but the intimate site and mechanism of interaction of CRF and CRF-related peptides, named urocortins (UCN1, UCN2, UCN3), with noradrenaline (NA) was not fully elucidated yet. Therefore, the aim of the present study was to investigate the actions of CRF and urocortins on the NA released from the rat locus coeruleus (LC), the primary source of NA in the brain, and the participation of CRF receptors (CRF1 and CRF2) in these actions. In order to do so, male Wistar rats were used, their LC were isolated and dissected, and the LC slices were incubated with tritium-labelled NA, superfused and stimulated electrically. During superfusion, the LC slices were treated with CRF, UCN1, UCN2 or UCN3, and, when significant effect was observed, pretreated with selective CRF1 antagonist antalarmin or selective CRF2 antagonist astressin2B. The release of tritium-labelled NA from the LC was determined by liquid scintillation counting. CRF and UCN1 increased significantly the tritium-labelled NA release from the LC, and these effects were reduced by antalarmin, but not by astressin2B. In addition, UCN2, but not UCN3, decreased significantly the tritium-labelled NA release from the LC, and this effect was reversed by astressin2B, but not antalarmin. Our results indicate the existence of two apparently opposing CRF systems in the LC, since activation of CRF1 by CRF and UCN1 stimulated, whereas activation of CRF2 by UCN2 inhibited the NA release. © 2024 
650 4 |a Általános orvostudomány 
700 0 1 |a Kovács Alíz  |e aut 
700 0 1 |a Palotai Miklós  |e aut 
700 0 1 |a Bagosi Zsolt  |e aut 
856 4 0 |u http://publicatio.bibl.u-szeged.hu/37900/1/TancsicsPatricia_Theeffectsofcorticotropin-releasingfactorCRFandurocortinsonthenoradrenalineNAreleasedfromthelocuscoeruleusLC.pdf  |z Dokumentum-elérés